Stay updated with breaking news from Mohamed Eid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in...
The FDA has accepted the sNDA for empagliflozin to improve glycemic control plus diet and exercise in patients aged ≥10 years with type 2 diabetes.
The FDA has accepted the sNDA for empagliflozin to reduce the risk of kidney disease progression and CV death in adults with chronic kidney disease.
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) ...
Ridgefield-based Boehringer Ingelheim reported the U.S. Food and Drug Administration has accepted a supplemental New Drug Application (sNDA) for Jardiance as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).